Definium Therapeutics (DFTX) Other financing activities (2024 - 2025)
Definium Therapeutics (DFTX) reported Other financing activities of $447000.0 for Q4 2025, up 104.19% on a QoQ basis from -$10.7 million in Q3 2024.
Definium Therapeutics (DFTX) has 2 years of Other financing activities data on file, last reported at $447000.0 in Q4 2025.
- Quarterly Other financing activities changed N/A year-over-year to $447000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $447000.0 (up 249.22% YoY) and the FY2025 annual result came in at $447000.0, up 249.22% from the prior year.
- Other financing activities climbed to $447000.0 in Q4 2025 per DFTX's latest filing, from -$10.7 million in the prior quarter.
- Across five years, Other financing activities topped out at $8.7 million in Q1 2024 and bottomed at -$10.7 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 447,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2024 | -10.68 Mn |
| Sep 30, 2024 | -10.68 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 8.72 Mn |
| Mar 31, 2024 | 8.72 Mn |